Cytosorbents (CTSO) Profit After Tax Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 18.66% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 13.84% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -27.98% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 14.60% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 71.04% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 12.92% |
| 10 | Cytosorbents | 23.26 Mn | 18.85 Mn | 7.05 Mn | -326.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -326.86% |
| Mar 31, 2026 | -246.79% |
| Dec 31, 2025 | 27.36% |
| Sep 30, 2025 | -14.52% |
| Jun 30, 2025 | 145.34% |
| Mar 31, 2025 | 75.71% |
| Dec 31, 2024 | -23.34% |
| Sep 30, 2024 | 69.87% |
| Jun 30, 2024 | 34.95% |
| Mar 31, 2024 | 16.85% |
| Dec 31, 2023 | -700.76% |
| Sep 30, 2023 | 24.69% |
| Jun 30, 2023 | 39.32% |
| Mar 31, 2023 | 18.33% |
| Dec 31, 2022 | 91.77% |
| Sep 30, 2022 | -90.45% |
| Jun 30, 2022 | -132.58% |
| Mar 31, 2022 | -115.13% |
| Dec 31, 2021 | -1,273.27% |
| Sep 30, 2021 | -662.90% |